Filtered Image?height=270

News & Publications

News & insights

AI and the use of data in the life sciences sector
Posted: 24/06/2024
AI is having a major impact on life sciences. Its ability to process vast quantities of data and information faster than humans has numerous valuable applications in the sector, from creating new drugs and targets, to use in medical devices to diagnose disease, as well as monitoring patients remotely, and analysing data, for example from MRI......>>
Penningtons Manches Cooper advises Delta Hat on acquisition by Petauri
Posted: 20/06/2024
The corporate team at Penningtons Manches Cooper has advised the shareholders of Delta Hat on its acquisition by Petauri. Delta Hat provides industry leading analysis and health economic modelling to the life sciences and healthcare sectors. Petauri is a purpose-built pharmaceutical services platform based in Nashville, Tennessee, USA......>>
Penningtons Manches Cooper advises Oxford Endovascular on £8 million funding round
Posted: 30/05/2024
The corporate team at Penningtons Manches Cooper has advised Oxford University spin-out Oxford Endovascular Ltd on securing its £8 million Series A+ funding round led by Parkwalk. Oxford Endovascular, founded in 2015, is a medtech start-up pioneering an innovative method using origami-inspired techniques to prevent brain haemorrhages......>>
Penningtons Manches Cooper advises Metrion Biosciences on £3.7 million funding round
Posted: 12/01/2024
The corporate team at Penningtons Manches Cooper has advised leading contract research organisation (CRO) Metrion Biosciences on securing its £3.7 million funding round led by Maven Capital Partners, alongside Gresham House Ventures. Cambridge-based Metrion specialises in providing high quality preclinical ion channel drug discovery......>>
Penningtons Manches Cooper acts for SkinBioTherapeutics PLC on placing and retail offer on AIM
Posted: 13/12/2023
The corporate team at Penningtons Manches Cooper has advised SkinBioTherapeutics plc (AIM: SBTX) on a £3 million placing and a separate retail offer to existing shareholders through the Bookbuild platform, raising an additional £250,000. This is the third fundraising on AIM that Penningtons Manches Cooper has advised......>>

Read all Life sciences news & insights

Publications

E-Bulletins

BioBrief - August 2023
In this edition of BioBrief, we look in detail at a recent case involving university-generated intellectual property and in particular the position of students who contribute to such IP. On a related topic, I give some practical, high-level guidance on the legal position relating to the ownership of inventions when outside consultants are involved.

BioBrief - April 2023
Following recent shockwaves throughout the sector caused by the demise of SVB, in this month’s BioBrief, we provide a link to a timely discussion of the funding options for early stage life sciences companies, published by our friends at OBN.

BioBrief - November 2022
A key strategic issue for many seeking partnerships with Big Pharma or other sources of funding is the robustness of the patent portfolio. IP issues feature in two contributions to this month’s BioBrief: in the first, my colleague Dr Amanda Easey and I present a videocast on the recent decision of the Patents Court.

BioBrief - May 2022
Welcome to the spring edition of BioBrief. We start this edition with an article I wrote recently for OBN Connect magazine which covers the challenges faced by Biotech founders on spin-out and the career change it requires. This is something that I am familiar with as I changed my career from project manager of global clinical trials for IQVIA to being an IP lawyer.

BioBrief - Winter 2021
Welcome to the winter edition of BioBrief. It has certainly been a very busy year for the life sciences industry! Colleagues across our team have been involved in interesting projects, in particular in terms of commercial deals and corporate transactions. We are delighted to report that, amongst others, we advised the shareholders of molecular diagnostics company ATDBio on its sale to NASDAQ Stockholm listed Biotage AB for approximately £45m..

View all life sciences e-bulletins

Return to Life sciences

Filter publications

Filter by keyword: Filter by expertise: Filter by publication type:

In this section

Media enquiries

Contact our press team on:

+44 (0)20 7457 3258
+44 (0)7887 888105 (out of hours)

Useful links

Value

Contact an office

London (Head office)
+44 (0)20 7457 3000
Basingstoke
+44 (0)1256 407100
Birmingham
+44 (0)121 312 2560
Cambridge
+44 (0)1223 465465
Guildford
+44 (0)1483 791800
Oxford
+44 (0)1865 722106
Reading
+44 (0)118 982 2640

Madrid
+34 91 781 6670
Paris
+33 1 44 34 24 80
Piraeus
+30 210 361 4840
Singapore
+65 6438 4497

Sectors

Services for Business

Services for Individuals

Copyright

© 2024 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.